These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 15623594)

  • 21. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
    Dziadziuszko R; Witta SE; Cappuzzo F; Park S; Tanaka K; Danenberg PV; Barón AE; Crino L; Franklin WA; Bunn PA; Varella-Garcia M; Danenberg KD; Hirsch FR
    Clin Cancer Res; 2006 May; 12(10):3078-84. PubMed ID: 16707605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR polymorphism of the kinase domain in Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Tanaka H; Kitahara N; Matsumura A; Iuchi K; Kawaguchi T; Okuda K; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    J Surg Res; 2008 Aug; 148(2):260-3. PubMed ID: 18541260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
    Wu JY; Wu SG; Yang CH; Gow CH; Chang YL; Yu CJ; Shih JY; Yang PC
    Clin Cancer Res; 2008 Aug; 14(15):4877-82. PubMed ID: 18676761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
    Rosell R; Ichinose Y; Taron M; Sarries C; Queralt C; Mendez P; Sanchez JM; Nishiyama K; Moran T; Cirauqui B; Mate JL; Besse B; Reguart N; Perez M; Sanchez JJ
    Lung Cancer; 2005 Oct; 50(1):25-33. PubMed ID: 16011858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
    Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
    Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
    Takano T; Ohe Y; Tsuta K; Fukui T; Sakamoto H; Yoshida T; Tateishi U; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Matsuno Y; Furuta K; Tamura T
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5385-90. PubMed ID: 17875767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
    Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
    Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
    Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
    Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
    Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
    Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
    Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
    Endo K; Sasaki H; Yano M; Kobayashi Y; Yukiue H; Haneda H; Suzuki E; Kawano O; Fujii Y
    Oncol Rep; 2006 Sep; 16(3):533-41. PubMed ID: 16865253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
    Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.